Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 13, 2022 08:00 ET | Source: Alector, Inc.

Alector Announces Promotion of Clare Hunt to Chief People Officer

Promotion demonstrates Alector’s commitment to building a world-class culture that questions convention, embraces feedback and promotes development for all employees Company recently earned...
October 06, 2022 16:30 ET | Source: Alector, Inc.

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today...
September 12, 2022 07:00 ET | Source: Alector, Inc.

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer’s Disease (AD)

AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD AL044, a novel first-in-class therapeutic candidate, seeks to counteract multiple AD pathologies...
September 07, 2022 07:00 ET | Source: Alector, Inc.

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
August 04, 2022 16:05 ET | Source: Alector, Inc.

Alector Reports Second Quarter 2022 Financial Results and Provides Business Update

Investigational New Drug Application submitted for AL044, a novel drug candidate targeting an Alzheimer’s disease risk gene Expanding clinical sites to drive additional enrollment in the INFRONT-3...
June 08, 2022 07:00 ET | Source: Alector, Inc.

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will...
May 27, 2022 16:30 ET | Source: Alector, Inc.

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation...
May 05, 2022 16:05 ET | Source: Alector, Inc.

Alector Reports First Quarter 2022 Financial Results and Provides Business Update

Data from INFRONT-2 Phase 2 clinical trial showed that FTD-C9orf72 patients treated with AL001 (latozinemab) demonstrated a trend towards an annual delay in disease progression of approximately 54...
May 04, 2022 07:00 ET | Source: Alector, Inc.

Alector to Participate at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will...
March 29, 2022 16:05 ET | Source: Alector, Inc.

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of...